GLP-1 Semaglutide 60mg (20mg/1mL)

Route: Subcutaneous (SC) injection, once weekly.

Draw the prescriber-specified dose volume from the multi-dose vial using a precision syringe with a new sterile needle for each use. Administer subcutaneously into the abdomen, outer thigh, or upper arm, rotating sites within the same body region each week. Do not administer IV or IM. Do not mix with insulin in the same syringe. Maintain aseptic technique at each vial access. At 20 mg/mL, the dose volume is half that of a 10 mg/mL preparation for the same mg dose — confirm exact volume with prescriber before injecting. Discard vial after the beyond-use date or if solution appearance changes.

All dosing is prescriber-determined. At 20 mg/mL concentration, volume calculations differ from lower-concentration vials:

• 1 mg dose = 0.05 mL (precision syringe required)
• 2.4 mg dose (Wegovy® equivalent maintenance) = 0.12 mL

Standard titration framework (based on FDA-approved product precedent):

• Starting (if not previously on semaglutide): 0.25 mg SC once weekly × 4 weeks.
• Escalation: Increase by 0.25–0.5 mg every 4 weeks as tolerated toward target.
• Maintenance (prescriber-directed): Typically 0.5–2.4 mg weekly. The 60 mg/3 mL vial provides approximately 25 weeks' supply at 2.4 mg/week (Wegovy® maintenance), supporting long-term continuous therapy.
• Pause escalation during significant GI adverse events and reassess with the prescriber.

• Semaglutide: Binds GLP-1R (Gs-coupled GPCR) with high affinity, activating adenylyl cyclase and increasing intracellular cAMP in target cells. Pancreatic β-cells: glucose-dependent insulin secretion enhancement (insulin release only when blood glucose is elevated, limiting hypoglycemia risk) and β-cell proliferation, with simultaneous α-cell glucagon suppression reducing hepatic glucose output. Gastrointestinal tract: delayed gastric emptying, reducing rate of nutrient absorption and postprandial glucose excursions. Hypothalamus: appetite suppression via arcuate and paraventricular nucleus GLP-1R signaling, enhancing satiety and reducing food intake. Structural modifications (C18 fatty diacid chain for albumin binding; Aib substitution at position 8 for DPP-4 resistance) enable the ~7-day half-life that distinguishes semaglutide as the longest-acting GLP-1RA available. Mechanism is identical to all semaglutide formulations regardless of concentration or vial size.

Clinical Context: The 60 mg/20 mg/mL vial is optimized for patients on established maintenance semaglutide therapy for type 2 diabetes glycemic control or chronic weight management. The large total dose volume reduces dispensing frequency, which improves adherence for chronic long-term therapy. Prescribers should:

• Confirm the patient is appropriately titrated before prescribing this high-volume vial.
• Provide explicit dose-volume tables to avoid medication administration errors at the 20 mg/mL concentration.
• Apply the same evidence-based monitoring framework as for all semaglutide preparations: HbA1c reduction (typical ~1.5% for T2DM), body weight reduction (~15% for obesity), and cardiovascular outcome benefit in patients with T2DM and established CVD (consistent with SUSTAIN-6 data).

Monitoring Considerations: HbA1c and fasting glucose; body weight and BMI; renal function; thyroid evaluation; retinal assessment in diabetic retinopathy patients; GI symptom burden; gallbladder and pancreatic symptom surveillance. Annual or semi-annual follow-up minimum for established patients on maintenance dosing.

Contraindications:

• Personal or family history of medullary thyroid carcinoma (MTC) or multiple endocrine neoplasia type 2 (MEN2).
• Type 1 diabetes mellitus.
• Known hypersensitivity to semaglutide or any excipient.

Warnings & Precautions:

• Black Box Warning — Thyroid C-cell tumors: Dose-dependent thyroid C-cell tumors observed in rodent studies; human relevance unknown. Contraindicated in MTC/MEN2 history. All patients require counseling.
• Dosing error risk at higher concentration: The 20 mg/mL concentration requires careful volume measurement; errors in volume calculation could result in significant over- or underdosing. Provide patients with written dose-volume reference and verify understanding before dispensing.
• Pancreatitis, cholecystitis, cholelithiasis, acute kidney injury, diabetic retinopathy worsening, suicidal ideation: same monitoring and precautions as all semaglutide products.
• Rebound weight gain: two-thirds of weight regained within ~12 months of discontinuation in weight management populations.

Drug Interactions:

• Insulin, sulfonylureas: increased hypoglycemia risk at initiation or dose escalation.
• Narrow therapeutic index oral medications: gastric emptying delay may affect absorption.
• Other GLP-1 agonists or tirzepatide: contraindicated in combination.
• Corticosteroids, thiazide diuretics, furosemide: may attenuate glycemic benefit.

Common Side Effects: Nausea, vomiting, diarrhea, constipation, abdominal pain, decreased appetite, dysgeusia, dyspepsia (predominate during titration). Injection-site reactions (erythema, mild pain). Fatigue, headache, alopecia with weight-loss protocols. GI adverse events are the primary cause of treatment discontinuation.

Store at 2–8°C (36–46°F) under refrigeration. Protect from light — keep vial in carton between uses. Do not freeze; peptide degradation occurs at freezing temperatures. Maintain strict aseptic technique at every vial access — use a new sterile needle and syringe for each weekly dose. Store the accessed multi-dose vial refrigerated and use within the beyond-use date (BUD) assigned by Genesis Compounding on the prescription label. Allow the drawn dose to reach room temperature briefly before injection. Discard vial and contents if solution appears cloudy, discolored, or particulate matter is visible.

This vial says 60 mg — does that mean I take 60 mg per week?

No. The vial contains 60 mg total semaglutide, which is the entire vial supply for multiple weeks of once-weekly dosing. Your weekly dose is the amount your prescriber specifies — for example, 0.5 mg, 1 mg, or 2.4 mg — and you draw only that prescribed volume each week. At 20 mg/mL, for example, a 1 mg weekly dose is only 0.05 mL. Always use the volume your prescriber specifies.

How many weeks does this vial last?

At 2.4 mg/week (Wegovy® maintenance dose equivalent), the 60 mg vial provides approximately 25 weeks of treatment. At 1 mg/week, it would last approximately 60 weeks. Your prescriber and pharmacist can calculate your expected days' supply based on your prescribed weekly dose.

Is this the same as the brand-name semaglutide products?

The active ingredient, semaglutide, is the same GLP-1 receptor agonist. However, this is a 503A compounded preparation from Genesis Compounding, not an FDA-approved branded product. It is prepared to meet your individual prescription needs under prescriber direction.

What if I lose power and my refrigerator warms up?

Semaglutide should be returned to refrigeration as promptly as possible. Brief excursions to room temperature (up to 25°C) for limited periods may be acceptable, but this should be discussed with your pharmacist. Do not use the vial if it has been left unrefrigerated for an extended or unknown period of time.

Do I need to use this forever for weight management?

Long-term therapy is typically required for sustained weight management benefits. Studies show that approximately two-thirds of weight lost is regained within 12 months of stopping semaglutide. Your prescriber will guide decisions about continuation, dose adjustment, or transition to another management strategy based on your ongoing goals and health status.